Business
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical
About this update from Bioatla, Inc.
[{"type":"text","content":"Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient derived pancreatic cancer modelNo clinical and histopathologic signs of toxicities in non-human primates with conditionally active tetravalent B7-H3 x CD3 T-cell engager (BA3142) SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024. Presentation Details: Poster Title: Using a novel NextGen linker system to generate a Conditionally Active Biologic (CAB) anti-Nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primatesAuthors: Jing Wang, Jian Chen, Gerhard Frey, Haizhen Liu, Charles Xing, Kathryn Woodard, Cathy Chang, William J. Boyle, and Jay M. ShortPoster Number: 743 / 29Session: PO.ET02.06 - Tumor MicroenvironmentDate / Time: Sunday, April 7, 2024 / 1:30 – 5:00 PM PTLocation: Section 29 Poster Title: Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid TumorsAuthors: Ana Paula Cugnetti, Haizhen Liu, Patricia McNeeley, Charles Xing, Kathryn Woodard, Cathy Chang, Gerhard Frey, William J. Boyle, and Jay M. ShortPoster Number: 6340 / 1Session: PO.CL06.08 - Antibodies 2Date / Time: Tuesday, April 9, 2024 / 1:30 – 5:00 PM PTLocation: Section 41 Poster Title: Novel Conditionally Active Biologic (CAB) tetravalent T-cell engagers targeting solid tumorsAuthors: Ana Paula Cugnetti, Haizhen Liu, Patricia McNeeley, Charles Xing, Kathryn Woodard, Cathy Chang, Gerhard Frey, William J. Boyle, and Jay M. ShortPoster Number: 744 / 30Session: PO.ET02.06 - Tumor MicroenvironmentDate / Time: Sunday, April 7, 2024 / 1:30 – 5:00 PM PTLocation: Section 29 Poster Title: Targeting novel senescence markers by Conditionally Active Biologics eliminates senesce...